

# TIGER Trial News

[www.anzup.org.au](http://www.anzup.org.au)

## Welcome to our fifth TIGER newsletter

It's great to see that globally the TIGER trial has recruited 286 patients to date. I would also like to thank the principal investigators, co-investigators, study co-ordinators and research teams at all the participating sites for your ongoing commitment and support to the study throughout these difficult and unprecedented times with COVID-19. Also a warm welcome to the TIGER Trial Operations Coordinator – Joe Levitt. As always please consider any cross referral opportunities and don't hesitate to get in contact if you have any questions regarding the TIGER study.

*TIGER Study Chair A/Professor Peter Grimison*

### Recruitment update

Global recruitment at 28 July 2020 is at 286/420 patients randomised to the trial. Congratulations to Chris O'Brien Lifeshouse who have recruited 2 patients to this total in 2020. This is a great achievement given COVID-19 challenges and the rarity of this patient population. Please reach out to colleagues within your state regarding the trial, and encourage cross-referral of suitable patients.

### Australian recruitment by site

Site	Principal Investigator	Activation Date	Screened	Enrolled
Princess Alexandra Hospital	Euan Walpole	10 Aug 2018	2	1
Eastern Health	Ian Davis	18 Sept 2018	1	1
Chris O'Brien Lifeshouse	Peter Grimison	26 Sept 2018	4	4
Peter MacCallum Cancer Care	Jeremy Lewin	31 Oct 2018	1	1
TOTAL			8	7
TARGET RECRUITMENT			60 patients	

Please continue to use the randomisation checklist to screen potential patients at your site. If there are any questions regarding a patient's eligibility, please contact the TIGER trials team at [tiger@ctc.usyd.edu.au](mailto:tiger@ctc.usyd.edu.au).

### TIGER STUDY CHAIR

**A/Professor  
Peter Grimison**



### What is TIGER?

A Randomised Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilising Paclitaxel plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumours (ANZUP 1604)  
Current approved protocol: V8.0

### TIGER key contacts:

Clinical trial operations:  
[tiger@ctc.usyd.edu.au](mailto:tiger@ctc.usyd.edu.au)

Sponsor queries  
(payments, contracts)  
Nisha Rana:  
[trials@anzup.org.au](mailto:trials@anzup.org.au)

### Audit:

TIGER site audits have been on hold due to the COVID-19 pandemic. Thanks to all sites for keeping us updated on how you are managing onsite visits during this rapidly changing environment.

### Hints and Tips:

1. Investigators and site staff need to ensure their CTEP account is renewed annually. The NHMRC Clinical Trials Centre will send reminders and assist you through this process. Please contact the TIGER mailbox if you have any questions regarding your account.
2. Please note that tumour markers (AFP HCG LDH) are required to be collected on both day 1 and day 15 of protocol chemotherapy, both for Arm A (TIP) cycles 1-4 and Arm B (TI-CE) cycles 3-5. This is detailed in footnote 3 of the study calendar within section 5.0 of the protocol.
3. Don't forget to send the COVID-19 Deviation logs fortnightly if there have been any new entries/deviations.

*The TIGER study team would like to wish you all good health and please not hesitate to get in touch if there's anything we can do to support you with the TIGER study.*

*We are grateful to the Movember Foundation for their financial support to conduct this study*



*TIGER is being led by ANZUP Cancer Trials Group in collaboration with the NHMRC CTC.*



*Alliance for Clinical Trials in Oncology is the Lead Group in the USA.*




*Below the Belt -*  
 YOUR WAY

1 - 30 September 2020  
[www.belowthebelt.org.au/yourway](http://www.belowthebelt.org.au/yourway)

### TIGER key contacts

- Clinical trial operations E: [tiger@ctc.usyd.edu.au](mailto:tiger@ctc.usyd.edu.au)
- Sponsor queries (e.g. site payments, contracts) E: [trials@anzup.org.au](mailto:trials@anzup.org.au) T: +61 2 8036 5271
- Coordinating PI: A/Prof Peter Grimison E: [peter.grimison@lh.org.au](mailto:peter.grimison@lh.org.au)
- Trial information: <https://www.anzup.org.au/content.aspx?page=trials-tiger>